ACADIA Pharmaceuticals Inc. (ACAD) Balance Sheet

NASDAQ: ACADAssets, liabilities, debt and equity over 10 years.

ACAD balance sheet, 2025

December 31, 2025 · U.S. dollars

$1.56B assets = $336.8M liabilities + $1.23B equity

What it owns$1.56BCash & ST investments: $819.7M (52.4%)Cash & ST investments$819.7M · 52%Receivables: $148.2M (9.5%)Receivables $148.2MInventory: $34.7M (2.2%)Other current: $59.5M (3.8%)PP&E: $54.9M (3.5%)Goodwill & intangibles: $108.9M (7.0%)$108.9MOther non-current: $338.3M (21.6%)Other non-current$338.3M · 22%=How it is financed$1.56BCurrent liabilities: $277.1M (17.7%)Current liabilities$277.1M · 18%Other LT liabilities: $59.7M (3.8%)Shareholders’ equity: $1.23B (78.5%)Shareholders’ equity$1.23B · 78%

Both columns are drawn to the same scale: what ACAD owns equals what it owes plus shareholders’ equity. Hover a block for its value.

ACAD financial health

Current ratio3.83
Comfortable · current assets cover current liabilities 3.83×
Debt / equity0.04
Low leverage · $0.04 of debt for each $1 of equity
Equity / assets78.5%
Equity-funded · of assets funded by shareholders
Cash / debt1,570.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles7.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

ACAD balance sheet trends, 2016–2025

ACADIA Pharmaceuticals Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$561.2M2016$1.56B2025+12.1%/yr
Total liabilities$42.7M2016$336.8M2025+25.8%/yr
Shareholders’ equity$518.4M2016$1.23B2025+10.0%/yr
Cash & short-term investments$529.0M2016$819.7M2025+5.0%/yr
Total debt$9.8M2019$52.2M2025+32.2%/yr
Net cash (debt)$687.6M2019$767.5M2025+$79.9M
Working capital$505.3M2016$785.0M2025+$279.7M
Book value per share$4.472016$7.162025+5.4%/yr
Current ratio12.8720163.832025−9.03
Debt / equity0.0120190.042025+0.03
Shares outstanding115.9M2016171.4M2025+4.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ACAD assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

ACAD liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

ACAD debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

ACAD balance sheet

ACADIA Pharmaceuticals Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$819.7M$756.0M$438.9M$416.8M$520.7M$632.0M$697.4M$473.5M$341.3M$529.0M
Cash & equivalents$177.7M$319.6M$188.7M$114.8M$147.4M$326.0M$189.7M$134.8M$69.4M$163.6M
Short-term investments$642.0M$436.4M$250.2M$302.0M$373.3M$305.9M$507.7M$338.8M$271.9M$365.4M
Receivables$148.2M$104.7M$102.3M$63.1M$65.3M$50.3M$37.9M$27.8M$18.4M$7.1M
Inventory$34.7M$21.9M$35.8M$6.6M$7.9M$9.7M$6.3M$4.1M$5.2M$4.2M
Other current assets$59.5M$55.7M$39.1M$21.4M$23.9M$25.7M$18.6M$20.7M$8.5M$7.5M
Total current assets$1.06B$938.3M$616.1M$507.9M$617.8M$717.6M$760.2M$526.1M$373.5M$547.9M
Property, plant & equipment (net)$54.9M$50.8M$56.5M$61.6M$66.3M$56.4M$12.7M$3.3M$2.7M$3.1M
Goodwill & intangible assets$108.9M$119.8M$65.5M$0$0$1.1M$2.6M$4.1M$5.5M$7.0M
Long-term investments$0$0$0$0$0$0$2.3M$1.3M$0$0
Other non-current assets$338.3M$78.9M$10.9M$18.3M$16.0M$7.4M$5.3M$5.4M$2.8M$3.2M
Total assets$1.56B$1.19B$749.0M$587.8M$700.1M$782.6M$783.2M$540.2M$384.5M$561.2M
Liabilities
Accounts payable$10.9M$16.2M$17.5M$12.7M$6.9M$8.5M$7.2M$3.2M$8.8M$3.9M
Short-term debt$11.6M$10.0M$9.4M$9.3M$8.3M$5.1M$3.4M———
Deferred revenue——$1.6M——————$2.6M
Total current liabilities$277.1M$394.9M$254.3M$125.6M$96.1M$106.0M$74.8M$59.6M$49.0M$42.6M
Long-term debt$0$0$0$0$0$0$0$0$0$0
Lease obligations$52.2M$52.0M$57.2M$62.0M$56.1M$44.5M$9.8M———
Other long-term liabilities$59.7M$60.1M$62.9M$61.8M$63.2M$49.6M$9.2M$1.6M$191,000$157,000
Total liabilities$336.8M$455.0M$317.2M$187.4M$159.2M$155.6M$84.0M$61.1M$49.2M$42.7M
Shareholders' equity
Common stock & paid-in capital$16,000$16,000$16,000$16,000$16,000$16,000$15,000$14,000$12,000$12,000
Retained earnings (deficit)−$1.81B−$2.20B−$2.43B−$2.37B−$2.15B−$1.99B−$1.70B−$1.47B−$1.22B−$934.0M
Treasury stock————————$0$0
Accumulated other comprehensive income$1.4M$292,000$24,000−$975,000−$192,000$36,000$297,000−$372,000−$399,000$106,000
Minority interest————————$0$0
Total shareholders' equity$1.23B$732.8M$431.8M$400.4M$540.9M$627.0M$699.1M$479.1M$335.3M$518.4M
Key figures
Total debt$52.2M$52.0M$57.2M$62.0M$64.4M$49.5M$9.8M———
Net cash (debt)$767.5M$704.0M$381.7M$354.8M$456.3M$582.4M$687.6M———
Working capital$785.0M$543.4M$361.9M$382.3M$521.8M$611.6M$685.4M$466.5M$324.4M$505.3M
Tangible book value$1.12B$613.0M$366.3M$400.4M$540.9M$625.9M$696.5M$475.0M$329.7M$511.4M
Book value per share$7.16$4.40$2.64$2.48$3.37$3.99$4.75$3.78$2.73$4.47
Shares outstanding171.4M166.4M163.8M161.7M160.5M157.3M147.2M126.6M122.6M115.9M
Current ratio3.832.382.424.046.436.7710.168.837.6212.87
Quick ratio3.492.182.133.826.106.449.838.427.3412.59
Debt / equity0.040.070.130.150.120.080.01———
Equity / assets78.5%61.7%57.6%68.1%77.3%80.1%89.3%88.7%87.2%92.4%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 25, 2026); data from EODHD.

ACAD financial position

At the end of fiscal 2025 (December 31, 2025), ACADIA Pharmaceuticals had total assets of $1.6 billion (up 31.7% from a year earlier), total liabilities of $336.8 million and shareholders' equity of $1.2 billion. It held $819.7 million in cash and short-term investments against $52.2 million of debt, a net cash position of $767.5 million. Its current ratio was 3.83. In the latest quarter (ended June 30, 2026) total assets were $1.7 billion and equity $1.3 billion.

Related: ACAD income statement, ACAD cash flow statement, ACAD key metrics. See the ACAD stock overview for the latest quote and news.

ACAD balance sheet FAQ

What are ACADIA Pharmaceuticals's total assets?

ACADIA Pharmaceuticals reported total assets of $1.6 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.2 billion a year earlier.

How much debt does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals had $52.2 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.04.

How much cash does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals held $819.7 million in cash and short-term investments at the end of fiscal 2025; with $52.2 million of debt that is net cash of $767.5 million.

What is ACADIA Pharmaceuticals's book value?

ACADIA Pharmaceuticals's shareholders' equity (book value) was $1.2 billion at the end of fiscal 2025, or $7.16 per share.

What is ACADIA Pharmaceuticals's current ratio?

ACADIA Pharmaceuticals had current assets of $1.1 billion and current liabilities of $277.1 million, a current ratio of 3.83 (it can cover its short-term obligations).

How much goodwill does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals carried $108.9 million of goodwill and intangible assets, 7.0% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet